KEY TAKEAWAYS
- The Phase 3 IMvigor211 and Phase 2 Cohort 1 study assessed the relationship between immune-related adverse events (irAEs) and oncological outcomes in patients undergoing immune checkpoint inhibitor (ICI) treatment.
- The findings suggest that experiencing irAEs is associated with improved disease progression risk, overall mortality, and cancer-specific mortality.
- The trials indicate a potential positive correlation between immune-related adverse events and better patient outcomes.
In this study to examine the link between immune-related adverse events (irAEs) and oncological results in individuals undergoing immune checkpoint inhibitors (ICI) treatment, researchers evaluated data from the IMvigor210 and IMvigor211 for advanced urothelial cancer.
The analysis involved 896 patients (pts) undergoing atezolizumab treatment for locally advanced or metastatic urothelial carcinoma. The data were accessed per Hoffmann–La Roche’s policy and made accessible through Vivli, Inc. To investigate the connection between the occurrence of immune-related adverse events (irAEs) and various clinical outcomes such as progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS), employed multivariable Cox regression or competing-risks regression when appropriate. Furthermore, the study stratified pts who experienced irAEs based on the administration of systemic corticosteroids.
In multivariable analysis, irAEs exhibited an inverse correlation with the disease progression’s risk [hazard ratio (HR) 0.50, 95% confidence interval (CI) 0.40-0.61, p<0.001], overall mortality [HR 0.51, 95% CI 0.41-0.64, p<0.001], and cancer-specific mortality [subdistribution hazard ratio (SHR) 0.55, 95% CI 0.45-0.72, p<0.001]. Furthermore, the utilization of systemic corticosteroids did not demonstrate an association with worsened oncological outcomes [PFS: HR 0.92, 95% CI 0.62-1.34, p=0.629; OS: HR 0.86, 95% CI 0.51-1.64, p=0.613; CSS: SHR 0.90, 95% CI 0.60-1.36, p=0.630].
Experiencing irAEs during atezolizumab treatment was linked to enhanced oncological outcomes. These results appear to remain unaffected by the administration of systemic corticosteroids.
Source: https://www.auajournals.org/doi/10.1097/JU.0000000000003240.11
Clinical Trial: https://classic.clinicaltrials.gov/ct2/show/NCT02302807
https://classic.clinicaltrials.gov/ct2/show/NCT02951767
Robesti, Daniele; Nocera, Luigi; Belladelli, Federico; Schultz, Julianne G.; Fallara, Giuseppe; Marandino, Laura; Raggi, Daniele; Montorsi, Francesco; Necchi, Andrea; Martini, Alberto PD09-11 THE IMMUNE-RELATED ADVERSE EVENTS PARADOX IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER PATIENTS RECEIVING ATEZOLIZUMAB: ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM IMvigor210 AND IMvigor211, Journal of Urology: April 2023 – Volume 209 – Issue Supplement 4 doi: 10.1097/JU.0000000000003240.11
